Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalotuzumab vs Cetuximab with Irinotecan in Metastatic Rectal Cancer
NCT01609231Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2012
- Primary completion
- Dec 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of dalotuzumab in rectal cancer, sponsored by Merck & Co.. Started Jul 2012; status: terminated.
02
Drugs
dalotuzumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01609231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01609231.